Navigation Links
YM BioSciences third quarter 2010 operational and financial results
Date:5/13/2010

---------------------------------------------- Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 1,084,901 $ 431,028 Accrued liabilities 2,142,707 486,723 Deferred revenue 1,527,596 2,549,568 ----------------------------------------------------------------------- 4,755,204 3,467,319 Deferred revenue 2,031,888 2,898,292 Shareholders' equity: Share capital 200,168,284 172,921,153 Share purchase warrants 1,473,246 - Contributed surplus 13,802,582 13,035,123 Deficit (158,621,155) (146,251,951) ----------------------------------------------------------------------- 56,822,957 39,704,325 Basis of presentation Commitments Subsequent event ------------------------------------------------------------------------- $ 63,610,049 $ 46,069,936 ------------------------------------------------------------------------- ------------------------------------------------------------------------- YM BIOSCIENCES INC. Interim Consolidated Statements of Operations, Comprehensive Income and Deficit (Expressed in Canadian dollars, unless otherwise indicated) ------------------------------------------------------------------------- Three months ended Nine months ended March 31, March 31, 2010 2009 2010 2009 -------------------------------------------------------------------------
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
3. YM BioSciences announces controlled equity offering
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
5. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
8. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
9. YM BioSciences closes US$17.5 million financing
10. YM BioSciences to raise approximately US$15 million
11. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/22/2014)... PA & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across ... Society for Clinical Data Management (SCDM) to provide ... and certification programs —providing access to the more ... partnership extends SCDM members with 10% off when registering ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... spotlight on the,ever-growing field of life sciences, Larta Institute,s ... in the midst of the dark backdrop of the,current ... to,focus on brilliant entrepreneurs in the life sciences, even ... years, through good,economic times and bad, the passion and ...
... 14 Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) announced ... & Renshaw 5th Annual Global Healthcare Conference to be ... in Monte Carlo, Monaco.,Jeffrey B. Davis, CEO of Access ... 3:10 pm local time, 9:10 am Eastern time and ...
... May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... has,received a letter of approval from the ... for its Clinical Trial Application (CTA),to begin ... administration of,REOLYSIN(R) in combination with paclitaxel and ...
Cached Biology Technology:Betting on Change - The Venture Forum in 2008 2Betting on Change - The Venture Forum in 2008 3Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2
(Date:12/11/2014)... 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ... condition and the best ways to treat it. ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... New knowledge points to the fact that a genetically ... skin barrier, plays a decisive role in the origin ... 3000 school-children scientists of the Helmholtz Zentrum Mnchen and ... the German population carry variations of the filaggrin gene, ...
... (MS), neuroradiologists and neurologists of the University hospitals of ... tissue damage, most of which had remained unrecognized up ... medium, Gadofluorine M, in magnetic resonance imaging. The scientists ... the renowned medical journal Brain . ...
... , Now that Olympia is approaching, the Chinese authorities ... large cities with different measures. For example, the car ... ordered not to use 70 percent of all company ... even or odd days - in accordance with their ...
Cached Biology News:When our protective armor shows weakness 2Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2GKSS membranes reduce air pollution in Beijing 2
... host strains are K-12 derivatives that have ... and glutathione reductase (gor) genes, which greatly ... Studies have shown that expression in Origami(DE3) ... another host even though overall expression levels ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... Kit, 1 kit. Convenient way ... Conjugations are carried out under mild ... Dyes are packaged in premeasured amounts ... Category: Blotting & Labeling & Detection, ...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: